Good morning and welcome everyone to the Liquidia Corporation full year 2024 financial result and corporate update conference call. My name is Shannon, and I will be your conference operator today.

Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

To date, participants have safely titrated to the study’s maximum dose twice daily, which is comparable to 26-28 breaths of Tyvaso® administered four times per day. The FDA has confirmed that a single ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against ...

Despite the unfavorable ruling for Liquidia, the regulatory exclusivity period for Tyvaso DPI is still set to expire on May 23, 2025. Additionally, United Therapeutics had filed a cross claim in the ...

The FDA was right to delay final approval of Liquidia Corp.'s lung-disease drug Yutrepia due to United Therapeutics Corp.'s exclusivity rights for the dry-powder-inhalation version of its blockbuster ...